University of Rochester

Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025. At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the ATS Research Program Benefit Networking Event, and the company is hosting the Jenesis Innovative Research Awards™ Ceremony. “Our series of posters and presentations at ATS will showcase the most recent findings on several products across our core portfolio and ongoing development pipeline,” said Andrew Nelsen, PharmD,Vice President, Global Medical Affairs at United Therapeutics. “We are pleased to present additional interim efficacy data from the ADVANCE EXTENSION open-label study evaluating ralinepag for pulmonary arterial hypertension, which has the potential, through once-daily dosing, to fundamentally change the positioning of prostacyclins in the treatment paradigm.” Posters, mini-symposia, and discussion sessions include: Thematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT: A48/P1624 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital. Thematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT: A48/P1623 – TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis: Preliminary Baseline Demographics. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital. Poster discussion session. Sunday, May 18, 2:15 p.m. to 4:15 p.m. PT: A104/908 – Expert Nurse Insights on the Future of Parenteral Prostacyclin Pumps for Pulmonary Arterial Hypertension. Presented by Lori Reed, N.P., Piedmont Healthcare. Rapid abstract poster discussion session. Monday, May 19, 9:15 a.m. to 11:15 a.m. PT: B26/410 – The Minimal Important Difference in NT-proBNP in Various Forms of Pulmonary Hypertension. Presented by Stephen Mathai, M.D., MHS, Johns Hopkins School of Medicine. Mini Symposium. Monday, May 19, 3:15 p.m. to 3:27 p.m. PT: B96 – Ralinepag Treatment to Achieve and Maintain REVEAL Lite 2 Low Risk Status: Interim Results of ADVANCE EXTENSION. Presented by Ray Benza, M.D., Icahn School of Medicine at Mount Sinai Center. Thematic poster session. Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT: C58/P1412 – Hemodynamic Phenotypes of Interstitial Lung Disease Patients Enrolled in the PHINDER Study. Presented by Debabrata Bandyopadhyay, MBBS, M.D., FCCP, FRCP, FACP, University of South Florida. Thematic poster session. Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT: C58/P1403 – Screening of Pulmonary Hypertension in Interstitial Lung Disease in the PHINDER Study: A Comparison of Physician Gestalt with Hemodynamics. Presented by Sandeep Sahay, M.D., Houston Methodist Hospital. Thematic poster session. Tuesday, May 20, 11:30 to 1:15 p.m. PT: C57/P1390 – Efficacy and Safety of Oral Treprostinil in Intermediate-High Risk Pulmonary Arterial Hypertension: A FREEDOM-EV Subgroup Analysis. Presented by Jim White, M.D., Ph.D., University of Rochester. Thematic poster session. Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT: C57/P1393 – Thrombocytopenia Associated with Epoprostenol and Treprostinil Alone and in Combination with Sotatercept. Presented by Mardi Gomberg-Maitland, M.D., M.Sc., George Washington University. Hosted/Sponsored events include: The 2025 Respiratory Innovation Summit, Friday, May 16 and Saturday, May 17. Andrew Nelsen, PharmD, United Therapeutics, will deliver a presentation at 1:00 p.m. PT on Saturday. The ATS Research Program Benefit, Saturday, May 17, 6:00 p.m. to 7:30 p.m. PT. The benefit will be held at the San Francisco Marriot Marquis. The Jenesis Innovative Research Awards Ceremony, Sunday, May 18, 6:30 p.m. to 9:30 p.m. PT. The ceremony will be held at the InterContinental Mark Hopkins San Francisco. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: unither.com/pbc. Forward-Looking Statements Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 21, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. JENESIS INNOVATIVE RESEARCH AWARDS is a trademark of United Therapeutics Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20250421355717/en/ Dewey Steadman at (202) 919-4097 (media/investors) Harry Silvers at (301) 578-1401 (investors) https://ir.unither.com/contact-uthr/ Source: United Therapeutics Corporation

Update on American Association for Cancer Research Annual Meeting 2025 presentationPRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii. Details of the presentation are as follows: Title: Broadly Protective Immunity against Influenza and Opportunities for Universal Influenza VaccinesSession Type: Guest Symposium Session Title: International Society of Influenza and Other Respiratory Viruses (ISIRIV) SymposiumDate, Time and Location: Sunday, May 4, 2025, 8:30–10:30 a.m. HST. Room 314 Presenter: Andrea Sant, Ph.D., Professor of Microbiology and Immunology at the University of Rochester Medical Center Separately, PDS Biotech announced that, due to new U.S. National Institutes of Health policies regarding employee attendance at scientific conferences and meetings, the abstract “Alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy,” submitted by the National Cancer Institute, will no longer be part of Poster Sessions at the American Association for Cancer Research Annual Meeting 2025. About PDS BiotechnologyPDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. For more information, please visit www.pdsbiotech.com Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune® HPV, PDS01ADC and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.   Infectimune® and Versamune® are registered trademarks of PDS Biotechnology Corporation. Investor Contact:Mike MoyerLifeSci AdvisorsPhone +1 (617) 308-4306 Email: mmoyer@lifesciadvisors.com Media Contact:Janine McCargo6 DegreesPhone +1 (646) 528-4034Email: jmccargo@6degreespr.com

Dr. Justin Houman, a fellowship-trained reproductive urologist in Beverly Hills, offers advanced microsurgical varicocelectomy to treat male infertility, chronic testicular pain, and low testosterone. His minimally invasive technique delivers proven results with faster recovery, helping men restore hormonal balance, improve fertility, and eliminate persistent discomfort. BEVERLY HILLS, Calif., April 7, 2025 /PRNewswire/ -- Dr. Justin Houman, a fellowship-trained reproductive urologist in Beverly Hills, is redefining male reproductive and hormonal health with a minimally invasive, precision-based approach to varicocele treatment. His advanced microsurgical varicocelectomy procedure is delivering powerful results for men suffering from infertility, persistent testicular pain, and low testosterone levels. Continue Reading Justin Houman MD. Affecting roughly 15% of all men and up to 40% of those evaluated for infertility, varicoceles—dilated veins in the scrotum—can disrupt sperm production, impair hormone levels, and cause chronic scrotal discomfort. Despite being common, they are often overlooked or misdiagnosed. "What many men don't realize is that varicoceles can impact more than fertility. They can affect testosterone, energy, libido, and quality of life," says Dr. Houman. "With the right surgical approach, we can address all of these issues—effectively and safely." A High-Precision, Outpatient Solution with Multiple Benefits Dr. Houman's microsurgical varicocelectomy is performed under a high power, surgical microscope, enabling unmatched precision and reduced risk to surrounding structures. This results in lower recurrence rates and faster recovery. Most patients return to regular activity in just 2–3 days following surgery. Benefits of Microsurgical Varicocelectomy: Fertility Enhancement: Boosts sperm count, motility, and morphology Pain Relief: Long-term resolution of dull, aching testicular pain Hormonal Health: Measurable increase in serum testosterone levels in many patients This advanced procedure is especially beneficial for men in their 20s to 40s who are trying to conceive, dealing with unexplained testicular discomfort, or experiencing symptoms of low testosterone. "Men deserve better than vague guidance or being told to 'wait and see,'" Dr. Houman adds. "This is a safe, highly effective, and life-changing option when offered to the right patient." About Dr. Justin Houman Dr. Justin Houman is a board-certified urologist and fellowship-trained male reproductive specialist proudly serving the Los Angeles community. He earned his medical degree from the University of Rochester School of Medicine, followed by a rigorous surgical internship and urology residency at the renowned Cedars-Sinai Medical Center. To further hone his expertise, Dr. Houman completed a prestigious fellowship in Male Reproductive Medicine and Surgery at UCLA Medical Center—one of the nation's top programs in the field. His advanced training and commitment to excellence have positioned him at the forefront of men's health and fertility care. Dr. Houman is an active member of several leading professional organizations, including the American Urological Association, Sexual Medicine Society of North America, International Society of Sexual Medicine, and the Los Angeles Urologic Society. Fluent in English, Spanish, and Farsi, he connects with patients from diverse backgrounds and is widely recognized for his compassionate bedside manner and deeply personalized approach to men's health. His ability to blend advanced medical expertise with genuine care has earned him the trust of patients and peers alike. His clinic is located at 8635 W 3rd St, Suite 1W, Los Angeles, CA. To learn more or schedule an appointment, visit or call 310-854-9898. Media Contact: Dr. Justin Houman Justin Houman MD 310-854-9898 [email protected] SOURCE Justin Houman MD. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED